3DP 4815

Drug Profile

3DP 4815

Latest Information Update: 03 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Class Antithrombotics
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arterial thrombosis; Venous thrombosis

Most Recent Events

  • 16 Apr 2003 3-Dimensional Pharmaceuticals has been acquired by Johnson & Johnson
  • 24 Jan 2001 Centocor has licensed 3DP 4815 from 3-Dimensional Pharmaceuticals for the world
  • 17 Feb 2000 Phase-I clinical trials for Arterial thrombosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top